(Total Views: 520)
Posted On: 11/27/2023 10:19:58 PM
Post# of 148870
Article: Clinical Challenges in Treating MASH:
“ Antifibrotic treatments cenicriviroc and simtuzumab may hold promise for MASH, and resmetirom -- a once-daily, oral THR-β selective agonist -- may be the most promising agent in the pipeline, said Jamile Wakim-Fleming, MD, director of the Center for Metabolic Steatosis of the Liver at the Cleveland Clinic.
Resmetirom, which is "designed to target key underlying causes of MASH in the liver and stabilize or improve fibrosis, is currently in a phase III clinical trial in patients with NASH and fibrosis (MAESTRO-NASHopens in a new tab or window) and hopefully will be approved in 2024," she told MedPage Today.
Primary findings from MAESTRO-NASH were reported earlier this yearopens in a new tab or window. They showed resolution of inflammation, ballooning, and disease activity in 26% of people on an 80-mg dose of resmetirom and 30% with a 100-mg dose, as compared with 10% of placebo patients (P<0.0001).”
https://www.medpagetoday.com/clinical-challen...definition
“ Antifibrotic treatments cenicriviroc and simtuzumab may hold promise for MASH, and resmetirom -- a once-daily, oral THR-β selective agonist -- may be the most promising agent in the pipeline, said Jamile Wakim-Fleming, MD, director of the Center for Metabolic Steatosis of the Liver at the Cleveland Clinic.
Resmetirom, which is "designed to target key underlying causes of MASH in the liver and stabilize or improve fibrosis, is currently in a phase III clinical trial in patients with NASH and fibrosis (MAESTRO-NASHopens in a new tab or window) and hopefully will be approved in 2024," she told MedPage Today.
Primary findings from MAESTRO-NASH were reported earlier this yearopens in a new tab or window. They showed resolution of inflammation, ballooning, and disease activity in 26% of people on an 80-mg dose of resmetirom and 30% with a 100-mg dose, as compared with 10% of placebo patients (P<0.0001).”
https://www.medpagetoday.com/clinical-challen...definition
(3)
(0)Scroll down for more posts ▼
